First patients enrolled in Evalve's post-market study

April 2009
Medical Device Daily;4/10/2009, Vol. 13 Issue 68, p1
The article reports on the enrollment of the first subject in the ACCESS-Europe study, a post-market observational study of Evalve's MitraClip for the percutaneous repair of cardiac valves. The MitraClip system is noted to be the first commercially available treatment in Europe and the U.S. for patients suffering from the effects of functional and degenerative mitral regurgitation (MR). The study will evaluate the system in patients up to 12 months after enrollment.


Related Articles

  • Evalve reports 1st Austrian implants of Mitracilp.  // Medical Device Daily;9/14/2009, Vol. 13 Issue 176, p7 

    The article reports on the treatment of the first group of patients with the MitraClip system from Evalve at the Elisabethinen Krankenhaus in Linz, Austria. According to Evalve, the MitraClip system is the only medical device commercially available in the European Union (EU) which offers a...

  • Evalve treats 1st patients at Swedish hospital.  // Medical Device Daily;8/25/2009, Vol. 13 Issue 163, p7 

    The article reports on the successful treatment of a group of patients who are suffering from the effects of functional and degenerative mitral regurgitation (MR) using Evalve's MitralClip system in Sweden. Evalve claims that MitralClip is the only medical device available in the European Union...

  • First 3 patients are treated at UK site with MitraClip.  // Medical Device Daily;12/9/2008, Vol. 12 Issue 218, p1 

    The article reports that Evalve of Menlo Park, California, the manufacturers of percutaneous heart valves said three patients have been treated with the MitraClip system at the University of Hull's Castle Hill Hospital in Great Britain. As stated, the MitraClip provides a non-surgical mitral...

  • Product Briefs.  // Biomedical Business & Technology;Mar2009, Vol. 32 Issue 3, p29 

    The article announces the start of enrollment for REALISM (Real World ExpAnded MuLtIcenter Study of the MitraClip System) study by Evalve. The system, a continued access registry, is under evaluation in the U.S. as a non surgical treatment option for patients suffering from the effects of mitral...

  • 1st MitraClip procedures done in Switzerland.  // Medical Device Daily;3/12/2009, Vol. 13 Issue 47, p3 

    The article reports on the successful treatment of the first series of patients using Evalve's MitraClip system at the Cardiocentro Ticino in Lugano, Switzerland. The system is a non-surgical mitral valve repair option for patients suffering from the effects of mitral regurgitation (MR) which is...

  • Evalve receives CE mark for its less-invasive MitraClip device.  // Medical Device Daily;3/27/2008, Vol. 12 Issue 60, p1 

    The article reports on the CE-mark approval received by Evalve, a developer of devices for percutaneous repair of cardiac valves, for its MitraClip system. The company claims that the product is the first commercially available device that provides patients suffering from the effects of mitral...

  • Evalve reports reduction of MR up to 36 months with MitraClip.  // Medical Device Daily;4/2/2007, Vol. 11 Issue 62, p4 

    The article presents an update related to the American College of Cardiology (ACC). Evalve reported that reduction of mitral regurgitation (MR) can be maintained for up to 3 years following treatment with its MitraClip device. Data from the bridge-to-transplantation (BTT) arm of the HeartMate II...

  • ACC Notebook.  // Medical Device Daily;3/31/2009, Vol. 13 Issue 60, p5 

    The article reports on the findings of a study on the use of MitraClip system from Evalve in percutaneous mitral valve repair. The study included high-risk surgical patients with functional mitral regurgitation (FMR) who were monitored for 12 months. It found that MitraClip improves the clinical...

  • FDA Advisory Committee OKs Abbott Lab's Mitral Regurgitation Device.  // Medical Product Outsourcing;Apr2013, Vol. 11 Issue 3, p38 

    The article discusses the approval of Mitral Regurgitation Device of the Abbott Laboratories by the U.S. Food and Drug Administration. The article discusses results of various clinical trials which are named as Everest II, Everest II High Risk and Realism. It is also mentioned that the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics